Currently serving as the Vice President of Market Access EU & International and Global HEOR in the Global Rare Disease Unit of Chiesi Group, Diana Sinkevich oversees market access and value strategies, health technology assessment, and evidence generation across Europe and international markets in all therapeutic areas within the Chiesi rare disease portfolio. Diana is committed to ensuring equal access to specialized care and innovative treatments for all PLWRD, striving to leave no patient behind through robust health economic evidence development despite the methodological limitations inherent in rare disease clinical data packages. Previously, Diana worked in various life sciences consulting companies, including IQVIA, where she focused on incorporating patients' perspectives into clinical trial design and translating clinical trials and real-world data into a language understandable to all healthcare decision-makers to achieve access for patients living with rare diseases (PLWRD) without delays. Diana received a master’s degree in Finance from Bocconi University, Milan, and in Biotechnology from John Hopkins University, Baltimore, as well as a bachelor’s degree in Economics from Bocconi University, Milan. She is currently based in Parma, Italy
Senior Representative, EVIDERA
Invited:
GBA, H-AS, NICE
Jakub Dvořáček, Deputy Minister, Ministry of Health of Czech Republic – tbc
Adrian Goretzki, President, Healthcare Education Institute – tbc